Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Summary

This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral blood stem cell transplantation (allo HSCT).

Timeline

Start

2020-04-10

Primary completion

2020-09-15

Completion

2021-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “the efficency is not good enough to enroll more patients”

Drugs

Indications